Abstract: The present disclosure discloses a damping device, a cooker and a device having a damping structure, wherein the damping device is arranged between a main body and a cover body, comprising a rotary member (2) fixed on the cover body; a fixed member (11) fixed on the main body, the fixed member (11) being a hollow body having openings at two ends, the rotary member (2) being nested in the hollow body, one of the rotary member (2) and an inner side wall of the hollow body being provided with a friction member (21), the other one being provided with an elastic piece (14); during the process of opening the cover body, the elastic piece (14) is slidably fitted with the friction member (21) and generates varying frictional resistance during sliding. The damping device is less susceptible to outside temperature and humidity and thus is less likely to fail.

Abstract: A ternary composite catalyst of diethylzinc and yttrium trifluoroacetate loaded on chitin for copolymerization of carbon dioxide, epoxy cyclohexane and ethylene oxide is provided. The ternary composite catalyst exhibits strong catalytic activity for the ternary copolymerization of carbon dioxide, cyclohexane oxide and ethylene oxide. A high molecular weight and content of ester chain is maintained. Conventional rare earth ternary catalysts leave residues in the polymer, and the polymer requires rinsing with hydrochloric acid. The ternary composite catalyst can be removed through filtration. The average molecular weight of the resulting polycarbonate is more than 100,000, and the ester chain content is more than 90%. The resulting polymer has a lower metal content. The ternary composite catalyst can be used in agricultural film, disposable packaging and other polymer materials.

Abstract: Disclosed is a charging station capable of realizing mutual capacity aid, which comprises a plurality of charging units, a power bus and a mutual capacity aid bus. Each charging unit is powered by the power bus, and each charging unit provides mutual aid capacity for another charging unit through the mutual capacity aid bus or receives mutual aid capacity from other charging units through the mutual capacity aid bus. The charging station can realize rapid charging of electric vehicles, and can also realize mutual capacity aid.

Abstract: This document relates to a pharmaceutical formulation of cabazitaxel with two compositions that are mixed prior to being infused or administered to patients, that comprises: (a) a first liquid composition comprising cabazitaxel and ethanol, and (b) a second aqueous composition comprising human serum albumin and a parenterally acceptable vehicle, and wherein the said pharmaceutical formulation does not contain a surfactant (e.g. Polysorbate 80).

Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

Abstract: A fully automatic peanuts peeling robot for seeds retention and a method using the same are provided. The robot includes a processing mechanism, a feeding mechanism and a screening mechanism. The processing mechanism includes an aluminum profile support bracket, a bracket assembly, a conveyor belt device, and a conversion device, a sensor device and a cut-off device; the aluminum profile support bracket is fixedly connected to the bracket assembly; the bracket assembly includes a first bracket assembly, a second bracket assembly, and a third bracket assembly; and the aluminum profile support bracket is fixedly connected to the conveyor belt device; the conveyor belt device includes a first conveyor belt assembly, a second conveyor belt assembly, and a third conveyor belt assembly; the conveyor belt device is fixedly connected to the conversion device.

Abstract: This document relates to a pharmaceutical formulation of docetaxel, or a pharmaceutically acceptable salt thereof, with two compositions that are mixed prior to being infused or administered to patients, that comprises: (a) a first liquid composition comprising docetaxel, or a pharmaceutically acceptable salt thereof, and ethanol, and (b) a second aqueous composition comprising human serum albumin and a parenterally acceptable vehicle, and wherein the said pharmaceutical formulation does not contain Polysorbate 80.

Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: A fully automatic peanuts peeling robot for seeds retention and a method using the same are provided. The robot includes a processing mechanism, a feeding mechanism and a screening mechanism. The processing mechanism includes an aluminum profile support bracket, a bracket assembly, a conveyor belt device, and a conversion device, a sensor device and a cut-off device; the aluminum profile support bracket is fixedly connected to the bracket assembly; the bracket assembly includes a first bracket assembly, a second bracket assembly, and a third bracket assembly; and the aluminum profile support bracket is fixedly connected to the conveyor belt device; the conveyor belt device includes a first conveyor belt assembly, a second conveyor belt assembly, and a third conveyor belt assembly; the conveyor belt device is fixedly connected to the conversion device.

Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.

Abstract: This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: This document relates to compositions comprising a non-covalently bound complex comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.